OTCPK:DSNKY (Japan)   Healthcare » Drug Manufacturers
Daiichi Sankyo Co Ltd logo

Daiichi Sankyo Co Ltd $ 25.86 -0.13 (-0.5%)

On watch
Volume:
20,619
Avg Vol (1m):
39,187
Market Cap $:
49.55 Bil
Enterprise Value $:
43.70 Bil
PE Ratio:
77.75
PB Ratio:
4.20
Warning! GuruFocus has detected 2 Medium warning signs with DSNKY. Click here to check it out.
Also Trade In: Germany Japan
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for DSNKY (Daiichi Sankyo Co Ltd) from 2008 to May 08 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Daiichinkyo stock (DSNKY) PE ratio as of May 08 2021 is 77.75. More Details

Daiichinkyo PE Ratio (TTM) Chart

EMBED

Daiichinkyo PE Ratio (TTM) Historical Data

Total 1227
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Daiichinkyo PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-05-08106.9 2021-03-08119.8
2021-05-07106.9 2021-03-05119.8
2021-05-06107.4 2021-03-04116.5
2021-05-05106.0 2021-03-03119.4
2021-05-04105.6 2021-03-02121.6
2021-05-03106.5 2021-03-01121.8
2021-04-30105.9 2021-02-26118.1
2021-04-29107.1 2021-02-25122.8
2021-04-28106.6 2021-02-24126.1
2021-04-27109.5 2021-02-23128.1
2021-04-26115.8 2021-02-22128.8
2021-04-23118.7 2021-02-19130.6
2021-04-22115.1 2021-02-18129.3
2021-04-21114.0 2021-02-17129.4
2021-04-20111.2 2021-02-16130.6
2021-04-19113.2 2021-02-15129.2
2021-04-16115.0 2021-02-12129.2
2021-04-15115.2 2021-02-11126.4
2021-04-14113.9 2021-02-10125.9
2021-04-13113.6 2021-02-09127.3
2021-04-12113.4 2021-02-08127.5
2021-04-09113.5 2021-02-05128.1
2021-04-08111.9 2021-02-04128.1
2021-04-07114.0 2021-02-03130.6
2021-04-06115.7 2021-02-02133.6
2021-04-05119.4 2021-02-01133.4
2021-04-02119.3 2021-01-29134.3
2021-04-01119.3 2021-01-28139.8
2021-03-31121.5 2021-01-27142.6
2021-03-30123.9 2021-01-26143.1
2021-03-29124.5 2021-01-25143.0
2021-03-26125.2 2021-01-22143.5
2021-03-25121.7 2021-01-21144.5
2021-03-24121.0 2021-01-20145.5
2021-03-23123.8 2021-01-19150.3
2021-03-22124.3 2021-01-15146.2
2021-03-19127.2 2021-01-14147.0
2021-03-18128.5 2021-01-13145.5
2021-03-17127.0 2021-01-12145.1
2021-03-16124.3 2021-01-11145.7
2021-03-15122.9 2021-01-08146.2
2021-03-12123.4 2021-01-07145.1
2021-03-11121.4 2021-01-06142.0
2021-03-10123.4 2021-01-05142.6
2021-03-09122.5 2021-01-04145.1

Daiichinkyo PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Daiichi Sankyo Co Ltd logo

Business Description

Traded in other countries
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo Co Ltd is a Japanese pharmaceutical company. It focuses on research and development for bringing up forth novel therapies in oncology, including immune oncology, with further focus on new areas, such as pain management, neurodegenerative diseases, heart and kidney diseases. Daiichi, through the pharmaceutical technology platform, develops processes for manufacturing of quality pharmaceuticals that meet desired efficacy and safety parameters. Daiichi is involved in process technology, biotechnology, formulation technology, analytical and quality evaluation technology. Its products brand includes PRALIA, MOVANTIK, LIXIANA, levofloxacin, Injectafer, and others. The company has its business operations in Europe, North America, and Japan. Most of its revenue comes from Japan.